MetaCap

OnKure Therapeutics (OKUR) vs Sionna Therapeutics (SION)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

OnKure Therapeutics (OKUR) has outperformed Sionna Therapeutics (SION) over the past year, gaining 4.7% versus a loss of 93.5%. Sionna Therapeutics is the larger company by market cap ($127.8 million vs $111.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

OKUR+4.65%SION-93.53%
+114%+5%-103%
Nov 21, 20251 yearNov 20, 2026
OKUR-53.85%SION-88.70%
+114%+8%-98%
Feb 3, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

OKUR versus SION key metrics
MetricOKURSION
Share price$2.70$2.83
Market cap$111.21M$127.79M
1-day change-2.17%-4.88%
YTD return-6.90%-93.13%
1-year return+4.65%-93.53%
5-year return-96.16%—
EPS (TTM)$-2.26$-2.43
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-59.52M$-75.27M
52-week high$5.38$54.97
52-week low$2.01$2.75
Distance from 52-week high-49.81%-94.86%
Analyst consensusnonehold
Avg. price target upside+464.81%+643.36%
Average volume335.78K1.12M
Shares outstanding40.50M45.24M
Employees4559
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OKUR has outperformed SION by 98.2 percentage points over the past year.

About OnKure Therapeutics

OKUR stock →

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 45 employees

About Sionna Therapeutics

SION stock →

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.

Health Care · Biotechnology: Pharmaceutical Preparations · 59 employees

OKUR vs SION FAQ

Which is bigger, OnKure Therapeutics or Sionna Therapeutics?

Sionna Therapeutics (SION) is larger, with a market capitalization of $127.79M compared with $111.21M for OnKure Therapeutics (OKUR).

Which stock has performed better over the past year, OKUR or SION?

OKUR returned +4.65% over the past 12 months, compared with -93.53% for SION (price return, excluding dividends). Past performance does not predict future results.

Are OnKure Therapeutics and Sionna Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons